Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Actinium Pharmaceuticals, Inc.ATNM · Entity 7435 | Director | March 14, 2017 | March 16, 2017 |
| RELMADA THERAPEUTICS, INC.RLMD · Entity 5498 | Director · Chief Executive Officer | September 09, 2026 | September 11, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Actinium Pharmaceuticals, Inc.
Report date March 14, 2017 · Filed March 16, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Options to purchase common stockSEC Table II · derivative / convertible security · Conversion / exercise price $1.39 · Expires 2027-03-14 | Direct | 75,000 |
Reported balance
After 2017-03-14 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2017-03-14 · Grant · Acquired 75,000 · Balance 75,000 F1: Pursuant to the terms of the company's Amended and Restated 2013 Stock Plan, 2% of the options shall vest each month from the date of grant. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to the terms of the company's Amended and Restated 2013 Stock Plan, 2% of the options shall vest each month from the date of grant.
RELMADA THERAPEUTICS, INC.
Report date September 09, 2026 · Filed September 11, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 1,500,000 |
Ending reported balance
After 2026-09-10 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-09-09 · Purchase · Acquired 100,000 · Balance 1,400,000 F1: The number of securities reported represents an aggregate number of shares purchased in multiple open market transactions over a range of purchase prices. The price reported represents the weighted average price. The Reporting Person undertakes to provide to the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares purchased by the Reporting Person at each separate price within the range. F2: Purchase prices range from $4.15 to $4.22 per share, inclusive. Row 2 · 2026-09-10 · Purchase · Acquired 100,000 · Balance 1,500,000 F1: The number of securities reported represents an aggregate number of shares purchased in multiple open market transactions over a range of purchase prices. The price reported represents the weighted average price. The Reporting Person undertakes to provide to the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares purchased by the Reporting Person at each separate price within the range. F3: Purchase prices range from $4.03 to $4.11 per share, inclusive |
Filing footnotes · ownership attribution and instrument terms
F1: The number of securities reported represents an aggregate number of shares purchased in multiple open market transactions over a range of purchase prices. The price reported represents the weighted average price. The Reporting Person undertakes to provide to the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares purchased by the Reporting Person at each separate price within the range.
F2: Purchase prices range from $4.15 to $4.22 per share, inclusive.
F3: Purchase prices range from $4.03 to $4.11 per share, inclusive
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 10, 2026 Filed Sep 11, 2026 11:30 UTC | RELMADA THERAPEUTICS, INC. RLMD · Entity 5498 | PurchaseCommon Stock | 100,000 | $4.10 | $410,000.00 |
DisclosureSEC source: 0001213900-26-098969 · ownership.xml · nonDerivative · entry 2 TRAVERSA SERGIO · CIK 0001565832 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,500,000 F1 · shares: The number of securities reported represents an aggregate number of shares purchased in multiple open market transactions over a range of purchase prices. The price reported represents the weighted average price. The Reporting Person undertakes to provide to the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares purchased by the Reporting Person at each separate price within the range. F3 · price: Purchase prices range from $4.03 to $4.11 per share, inclusive Read SEC document |
| September 09, 2026 Filed Sep 11, 2026 11:30 UTC | RELMADA THERAPEUTICS, INC. RLMD · Entity 5498 | PurchaseCommon Stock | 100,000 | $4.18 | $418,000.00 |
DisclosureSEC source: 0001213900-26-098969 · ownership.xml · nonDerivative · entry 1 TRAVERSA SERGIO · CIK 0001565832 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,400,000 F1 · shares: The number of securities reported represents an aggregate number of shares purchased in multiple open market transactions over a range of purchase prices. The price reported represents the weighted average price. The Reporting Person undertakes to provide to the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares purchased by the Reporting Person at each separate price within the range. F2 · price: Purchase prices range from $4.15 to $4.22 per share, inclusive. Read SEC document |
| December 15, 2025 Filed Dec 16, 2025 14:30 UTC | RELMADA THERAPEUTICS, INC. RLMD · Entity 5498 | PurchaseCommon Stock | 27,500 | $4.12 | $113,300.00 |
DisclosureSEC source: 0001213900-25-121974 · ownership.xml · nonDerivative · entry 1 TRAVERSA SERGIO · CIK 0001565832 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,300,000 F1 · shares: The number of securities reported represents an aggregate number of shares purchased in multiple open market transactions over a range of purchase prices. The price reported represents the weighted average price. The Reporting Person undertakes to provide to the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares purchased by the Reporting Person at each separate price within the range. F2 · price: Purchase prices range from $4.10 to $4.12 per share, inclusive. Read SEC document |
| December 12, 2025 Filed Dec 16, 2025 14:30 UTC | RELMADA THERAPEUTICS, INC. RLMD · Entity 5498 | GrantStock Appreciation Rights · Derivative | 1,198,000 | $0.00 Strike: $4.06 | $0.00 |
DisclosureSEC source: 0001213900-25-121974 · ownership.xml · derivative · entry 2 TRAVERSA SERGIO · CIK 0001565832 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,198,000 Underlying: Common Stock · 1,198,000 shares Expires 2035-12-12 F3 · derivative.exercise_date: The stock appreciation rights vest in 16 equal quarterly installments commencing on March 12, 2026. Read SEC document |
| November 05, 2025 Filed Nov 6, 2025 12:30 UTC | RELMADA THERAPEUTICS, INC. RLMD · Entity 5498 | PurchaseCommon Stock | 272,500 | $2.20 | $599,500.00 |
DisclosureSEC source: 0001213900-25-106837 · ownership.xml · nonDerivative · entry 1 TRAVERSA SERGIO · CIK 0001565832 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,272,500 Read SEC document |
| August 28, 2025 Filed Aug 28, 2025 20:56 UTC | RELMADA THERAPEUTICS, INC. RLMD · Entity 5498 | PurchaseCommon Stock | 55,976 | $0.74 | $41,422.24 |
DisclosureSEC source: 0001213900-25-081837 · ownership.xml · nonDerivative · entry 3 TRAVERSA SERGIO · CIK 0001565832 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,000,000 F1 · shares: The number of securities reported represents an aggregate number of shares purchased in multiple open market transactions over a range of purchase prices. The price reported represents the weighted average price. The Reporting Person undertakes to provide to the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares purchased by the Reporting Person at each separate price within the range. F4 · price: Purchase prices range from $0.68 to $0.79 per share, inclusive. Read SEC document |
| August 27, 2025 Filed Aug 28, 2025 20:56 UTC | RELMADA THERAPEUTICS, INC. RLMD · Entity 5498 | PurchaseCommon Stock | 129,455 | $0.67 | $86,734.85 |
DisclosureSEC source: 0001213900-25-081837 · ownership.xml · nonDerivative · entry 2 TRAVERSA SERGIO · CIK 0001565832 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 944,024 F1 · shares: The number of securities reported represents an aggregate number of shares purchased in multiple open market transactions over a range of purchase prices. The price reported represents the weighted average price. The Reporting Person undertakes to provide to the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares purchased by the Reporting Person at each separate price within the range. F3 · price: Purchase prices range from $0.65 to $0.69 per share, inclusive. Read SEC document |
| August 26, 2025 Filed Aug 28, 2025 20:56 UTC | RELMADA THERAPEUTICS, INC. RLMD · Entity 5498 | PurchaseCommon Stock | 80,545 | $0.62 | $49,937.90 |
DisclosureSEC source: 0001213900-25-081837 · ownership.xml · nonDerivative · entry 1 TRAVERSA SERGIO · CIK 0001565832 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 814,569 F1 · shares: The number of securities reported represents an aggregate number of shares purchased in multiple open market transactions over a range of purchase prices. The price reported represents the weighted average price. The Reporting Person undertakes to provide to the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares purchased by the Reporting Person at each separate price within the range. F2 · price: Purchase prices range from $0.61 to $0.65 per share, inclusive. Read SEC document |
| June 26, 2025 Filed Jun 30, 2025 23:28 UTC | RELMADA THERAPEUTICS, INC. RLMD · Entity 5498 | GrantStock Option (right to buy) · Derivative | 800,000 | $0.00 Strike: $0.67 | $0.00 |
DisclosureSEC source: 0001213900-25-059868 · ownership.xml · derivative · entry 1 TRAVERSA SERGIO · CIK 0001565832 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 800,000 Underlying: Common Stock · 800,000 shares Expires 2035-06-26 F1 · derivative.exercise_date: The options vest in 16 equal quarterly installments commencing on September 26, 2025. Read SEC document |
| May 20, 2025 Filed May 20, 2025 22:01 UTC | RELMADA THERAPEUTICS, INC. RLMD · Entity 5498 | PurchaseCommon Stock | 147,686 | $0.56 | $82,246.33 |
DisclosureSEC source: 0001213900-25-046085 · ownership.xml · nonDerivative · entry 3 TRAVERSA SERGIO · CIK 0001565832 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 734,024 F1 · shares: The number of securities reported represents an aggregate number of shares purchased in multiple open market transactions over a range of purchase prices. The price reported represents the weighted average price. The Reporting Person undertakes to provide to the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares purchased by the Reporting Person at each separate price within the range. F4 · price: Purchase prices range from $0.53 to $0.59 per share, inclusive. Read SEC document |
| May 19, 2025 Filed May 20, 2025 22:01 UTC | RELMADA THERAPEUTICS, INC. RLMD · Entity 5498 | PurchaseCommon Stock | 30,000 | $0.50 | $14,994.00 |
DisclosureSEC source: 0001213900-25-046085 · ownership.xml · nonDerivative · entry 2 TRAVERSA SERGIO · CIK 0001565832 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 586,338 F1 · shares: The number of securities reported represents an aggregate number of shares purchased in multiple open market transactions over a range of purchase prices. The price reported represents the weighted average price. The Reporting Person undertakes to provide to the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares purchased by the Reporting Person at each separate price within the range. F3 · price: Purchase prices range from $0.4998 to $0.50 per share, inclusive. Read SEC document |
| May 16, 2025 Filed May 20, 2025 22:01 UTC | RELMADA THERAPEUTICS, INC. RLMD · Entity 5498 | PurchaseCommon Stock | 172,314 | $0.45 | $77,472.37 |
DisclosureSEC source: 0001213900-25-046085 · ownership.xml · nonDerivative · entry 1 TRAVERSA SERGIO · CIK 0001565832 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 556,338 F1 · shares: The number of securities reported represents an aggregate number of shares purchased in multiple open market transactions over a range of purchase prices. The price reported represents the weighted average price. The Reporting Person undertakes to provide to the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares purchased by the Reporting Person at each separate price within the range. F2 · price: Purchase prices range from $0.4485 to $0.4564 per share, inclusive. Read SEC document |
| September 11, 2024 Filed Sep 11, 2024 21:47 UTC | RELMADA THERAPEUTICS, INC. RLMD · Entity 5498 | PurchaseCommon Stock | 51,407 | $2.99 | $153,706.93 |
DisclosureSEC source: 0001213900-24-077795 · ownership.xml · nonDerivative · entry 3 TRAVERSA SERGIO · CIK 0001565832 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 384,024 F1 · shares: The number of securities reported represents an aggregate number of shares purchased in multiple open market transactions over a range of purchase prices. The price reported represents the weighted average price. The Reporting Person undertakes to provide to the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares purchased by the Reporting Person at each separate price within the range. F4 · price: Purchase prices range from $2.84 to $3.05 per share, inclusive. Read SEC document |
| September 10, 2024 Filed Sep 11, 2024 21:47 UTC | RELMADA THERAPEUTICS, INC. RLMD · Entity 5498 | PurchaseCommon Stock | 33,014 | $2.75 | $90,788.50 |
DisclosureSEC source: 0001213900-24-077795 · ownership.xml · nonDerivative · entry 2 TRAVERSA SERGIO · CIK 0001565832 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 332,617 F1 · shares: The number of securities reported represents an aggregate number of shares purchased in multiple open market transactions over a range of purchase prices. The price reported represents the weighted average price. The Reporting Person undertakes to provide to the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares purchased by the Reporting Person at each separate price within the range. F3 · price: Purchase prices range from $2.73 to $2.80 per share, inclusive. Read SEC document |
| September 09, 2024 Filed Sep 11, 2024 21:47 UTC | RELMADA THERAPEUTICS, INC. RLMD · Entity 5498 | PurchaseCommon Stock | 55,579 | $2.71 | $150,619.09 |
DisclosureSEC source: 0001213900-24-077795 · ownership.xml · nonDerivative · entry 1 TRAVERSA SERGIO · CIK 0001565832 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 299,603 F1 · shares: The number of securities reported represents an aggregate number of shares purchased in multiple open market transactions over a range of purchase prices. The price reported represents the weighted average price. The Reporting Person undertakes to provide to the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares purchased by the Reporting Person at each separate price within the range. F2 · price: Purchase prices range from $2.51 to $2.85 per share, inclusive. Read SEC document |
| May 24, 2024 Filed May 30, 2024 01:25 UTC | RELMADA THERAPEUTICS, INC. RLMD · Entity 5498 | OtherStock Option (right to buy) · Derivative | 122,358 | $0.00 Strike: $2.48 | $0.00 |
DisclosureSEC source: 0001213900-24-047639 · ownership.xml · derivative · entry 2 TRAVERSA SERGIO · CIK 0001565832 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 183,881 Underlying: Common Stock · 122,358 shares Expires 2033-12-15 F2 · kind: On May 24, 2024, the Reporting Person voluntarily forfeited to the Issuer a portion of the December Award equal to the Additional Award Shares so that those shares can be allocated to the holders of Similar Awards who are not executive officers or directors of the Issuer. Read SEC document |
| May 24, 2024 Filed May 30, 2024 01:25 UTC | RELMADA THERAPEUTICS, INC. RLMD · Entity 5498 | GrantStock Option (right to buy) · Derivative | 122,358 | $0.00 Strike: $2.48 | $0.00 |
DisclosureSEC source: 0001213900-24-047639 · ownership.xml · derivative · entry 1 TRAVERSA SERGIO · CIK 0001565832 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 306,239 Underlying: Common Stock · 122,358 shares Expires 2033-12-15 F1 · kind: On May 24, 2024, under the terms of the option award granted to the Reporting Person on December 15, 2023 (the "December Award"), the Reporting Person became entitled to receive options for up to 122,358 additional shares of the Issuer's Common Stock on the same terms as the December Award (the "Additional Award Shares") out of shares that had become available under the terms of the Issuer's 2021 Equity Incentive Plan, as amended (the "Plan"), since December 15, 2023, as a result of expirations, cancelations, forfeitures and terminations of other outstanding awards under the Plan and/or tenders or withholding of shares. Read SEC document |
| January 31, 2024 Filed Jan 31, 2024 23:29 UTC | RELMADA THERAPEUTICS, INC. RLMD · Entity 5498 | PurchaseCommon Stock | 27,460 | $4.00 | $109,752.13 |
DisclosureSEC source: 0001213900-24-008560 · ownership.xml · nonDerivative · entry 3 TRAVERSA SERGIO · CIK 0001565832 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 244,024 F1 · shares: The number of securities reported represents an aggregate number of shares purchased in multiple open market transactions over a range of purchase prices. The price reported represents the weighted average price. The Reporting Person undertakes to provide to the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares purchased by the Reporting Person at each separate price within the range. F4 · price: Purchase prices range from $3.95 to $4.05 per share, inclusive. Read SEC document |
| January 30, 2024 Filed Jan 31, 2024 23:29 UTC | RELMADA THERAPEUTICS, INC. RLMD · Entity 5498 | PurchaseCommon Stock | 40,999 | $3.90 | $159,949.40 |
DisclosureSEC source: 0001213900-24-008560 · ownership.xml · nonDerivative · entry 2 TRAVERSA SERGIO · CIK 0001565832 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 216,564 F1 · shares: The number of securities reported represents an aggregate number of shares purchased in multiple open market transactions over a range of purchase prices. The price reported represents the weighted average price. The Reporting Person undertakes to provide to the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares purchased by the Reporting Person at each separate price within the range. F3 · price: Purchase prices range from $3.88 to $3.97 per share, inclusive. Read SEC document |
| January 29, 2024 Filed Jan 31, 2024 23:29 UTC | RELMADA THERAPEUTICS, INC. RLMD · Entity 5498 | PurchaseCommon Stock | 31,541 | $3.71 | $117,036.03 |
DisclosureSEC source: 0001213900-24-008560 · ownership.xml · nonDerivative · entry 1 TRAVERSA SERGIO · CIK 0001565832 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 175,565 F1 · shares: The number of securities reported represents an aggregate number of shares purchased in multiple open market transactions over a range of purchase prices. The price reported represents the weighted average price. The Reporting Person undertakes to provide to the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares purchased by the Reporting Person at each separate price within the range. F2 · price: Purchase prices range from $3.69 to $3.75 per share, inclusive. Read SEC document |
| December 15, 2023 Filed Dec 19, 2023 22:28 UTC | RELMADA THERAPEUTICS, INC. RLMD · Entity 5498 | GrantStock Option (right to buy) · Derivative | 183,881 | $0.00 Strike: $2.48 | $0.00 |
DisclosureSEC source: 0001213900-23-097032 · ownership.xml · derivative · entry 1 TRAVERSA SERGIO · CIK 0001565832 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 183,881 Underlying: Common Stock · 183,881 shares Expires 2033-12-15 F1 · derivative.exercise_date: The options vest in 16 equal quarterly installments commencing on March 15, 2024. Read SEC document |
| May 25, 2023 Filed May 30, 2023 21:10 UTC | RELMADA THERAPEUTICS, INC. RLMD · Entity 5498 | GrantStock Option (right to buy) · Derivative | 527,211 | $0.00 Strike: $3.37 | $0.00 |
DisclosureSEC source: 0001213900-23-044093 · ownership.xml · derivative · entry 1 TRAVERSA SERGIO · CIK 0001565832 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 850,728 Underlying: Common Stock · 527,211 shares Expires 2032-12-16 F1 · date: The option grant was approved by the Board of Directors of the Company on December 16, 2022, subject to shareholder approval of an amendment to the Company's 2021 Equity Incentive Plan, as amended (the "Plan"), increasing the number of shares of Common Stock available for the grant of awards under the Plan in an amount sufficient to cover this option grant. Shareholder approval was received for such amendment on May 25, 2023, at the 2023 Annual Meeting of the Company's shareholders. F2 · derivative.exercise_date: 80,728 of the options immediately vested; 770,000 options vest in 16 equal quarterly installments commencing on March 16, 2023. F2 · balance_after: 80,728 of the options immediately vested; 770,000 options vest in 16 equal quarterly installments commencing on March 16, 2023. Read SEC document |
| December 16, 2022 Filed Dec 21, 2022 00:31 UTC | RELMADA THERAPEUTICS, INC. RLMD · Entity 5498 | OtherStock Option (right to buy) · Derivative | 300,000 | Not disclosed Strike: $19.03 | Not disclosed |
DisclosureSEC source: 0001213900-22-081520 · ownership.xml · derivative · entry 1 TRAVERSA SERGIO · CIK 0001565832 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common stock · 300,000 shares Expires 2031-12-17 F1 · kind: Represents the termination of milestone-based stock options granted to the reporting person on May 25, 2022, that were eligible to vest based on achievement of certain corporate objectives by the Issuer. Upon grant, the target vesting amount was reported in Table II of Form 4. On December 16, 2022, the Board of Directors determined that such milestone objectives were not achieved by the Issuer and that all 300,000 options would be terminated. F1 · shares: Represents the termination of milestone-based stock options granted to the reporting person on May 25, 2022, that were eligible to vest based on achievement of certain corporate objectives by the Issuer. Upon grant, the target vesting amount was reported in Table II of Form 4. On December 16, 2022, the Board of Directors determined that such milestone objectives were not achieved by the Issuer and that all 300,000 options would be terminated. F2 · price: Not applicable. F2 · derivative.exercise_date: Not applicable. F3 · derivative.expiration_date: Original expiration date. Read SEC document |
| December 16, 2022 Filed Dec 20, 2022 22:34 UTC | RELMADA THERAPEUTICS, INC. RLMD · Entity 5498 | GrantStock Option (right to buy) · Derivative | 323,517 | $0.00 Strike: $3.37 | $0.00 |
DisclosureSEC source: 0001213900-22-081481 · ownership.xml · derivative · entry 1 TRAVERSA SERGIO · CIK 0001565832 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 323,517 Underlying: Common Stock · 323,517 shares Expires 2032-12-16 F1 · derivative.exercise_date: 80,728 of the shares are immediately vested; 242,789 shares vest in 16 equal quarterly installments commencing on March 16, 2023. Read SEC document |
| December 08, 2022 Filed Dec 13, 2022 01:00 UTC | RELMADA THERAPEUTICS, INC. RLMD · Entity 5498 | PurchaseCommon Stock | 55,250 | $2.10 | $115,804.00 |
DisclosureSEC source: 0001213900-22-079244 · ownership.xml · nonDerivative · entry 1 TRAVERSA SERGIO · CIK 0001565832 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 144,024 F1 · shares: The number of securities reported represents an aggregate number of shares purchased in multiple open market transactions over a range of purchase prices. The price reported represents the weighted average price. The Reporting Person undertakes to provide to the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares purchased by the Reporting Person at each separate price within the range. F2 · price: Purchase prices range from $2.05 to $2.13 per share, inclusive. Read SEC document |
| September 28, 2022 Filed Feb 6, 2023 22:39 UTC Amendment | RELMADA THERAPEUTICS, INC. RLMD · Entity 5498 | GiftStock Option (right to buy) · Derivative | 87,500 | $0.00 Strike: $33.43 | $0.00 |
DisclosureSEC source: 0001213900-23-008514 · ownership.xml · derivative · entry 7 TRAVERSA SERGIO · CIK 0001565832 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 162,500 Underlying: Common Stock · 87,500 shares Expires 2031-01-07 F1 · kind: Represents a bona fide gift of stock options to a family trust. An independent trustee is trustee of the trust. F7 · derivative.exercise_date: The options were granted on January 7, 2021. 25% of the options vested one year from the grant date, and thereafter in equal quarterly increments of 6.25% over the following three years. Read SEC document |
| September 28, 2022 Filed Feb 6, 2023 22:39 UTC Amendment | RELMADA THERAPEUTICS, INC. RLMD · Entity 5498 | GiftStock Option (right to buy) · Derivative | 62,500 | $0.00 Strike: $33.43 | $0.00 |
DisclosureSEC source: 0001213900-23-008514 · ownership.xml · derivative · entry 6 TRAVERSA SERGIO · CIK 0001565832 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 162,500 Underlying: Common Stock · 62,500 shares Expires 2031-01-07 F1 · kind: Represents a bona fide gift of stock options to a family trust. An independent trustee is trustee of the trust. F6 · derivative.exercise_date: The options were granted on January 7, 2021. 6.25% of the options vest each quarter from the date of grant. Read SEC document |
| July 01, 2022 Filed Jul 5, 2022 20:30 UTC | RELMADA THERAPEUTICS, INC. RLMD · Entity 5498 | Exercise / conversionStock Option (right to buy) · Derivative | 13,755 | $0.00 Strike: $16.00 | $0.00 |
DisclosureSEC source: 0001213900-22-037231 · ownership.xml · derivative · entry 9 TRAVERSA SERGIO · CIK 0001565832 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 13,755 shares Expires 2022-07-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction reported on this Form 4 reflects the exercise of stock options set to expire on July 10, 2022. F8 · derivative.exercise_date: The options were granted on July 10, 2012 (the "Grant Date"). 25% of the options vested upon the Grant Date and the remaining 75% of the options vested in equal quarterly increments over the next four (4) years, so that the last set of options vested in July 2016. Read SEC document |
| July 01, 2022 Filed Jul 5, 2022 20:30 UTC | RELMADA THERAPEUTICS, INC. RLMD · Entity 5498 | SaleCommon Stock | 4,068 | $18.32 | $74,525.76 |
DisclosureSEC source: 0001213900-22-037231 · ownership.xml · nonDerivative · entry 7 TRAVERSA SERGIO · CIK 0001565832 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 88,774 F2 · shares: The number of securities reported represents an aggregate number of shares sold in multiple open market transactions over a range of sales prices. The price reported represents the weighted average price. The Reporting Person undertakes to provide to the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares sold by the Reporting Person at each separate price within the range. F7 · price: Sales prices range from $18.26 to $18.44 per share, inclusive. Read SEC document |
| July 01, 2022 Filed Jul 5, 2022 20:30 UTC | RELMADA THERAPEUTICS, INC. RLMD · Entity 5498 | SaleCommon Stock | 8,848 | $18.45 | $163,245.60 |
DisclosureSEC source: 0001213900-22-037231 · ownership.xml · nonDerivative · entry 6 TRAVERSA SERGIO · CIK 0001565832 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 92,842 F2 · shares: The number of securities reported represents an aggregate number of shares sold in multiple open market transactions over a range of sales prices. The price reported represents the weighted average price. The Reporting Person undertakes to provide to the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares sold by the Reporting Person at each separate price within the range. F6 · price: Sales prices range from $18.45 to $18.47 per share, inclusive. Read SEC document |
| July 01, 2022 Filed Jul 5, 2022 20:30 UTC | RELMADA THERAPEUTICS, INC. RLMD · Entity 5498 | SaleCommon Stock | 839 | $18.48 | $15,504.72 |
DisclosureSEC source: 0001213900-22-037231 · ownership.xml · nonDerivative · entry 5 TRAVERSA SERGIO · CIK 0001565832 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 101,690 F2 · shares: The number of securities reported represents an aggregate number of shares sold in multiple open market transactions over a range of sales prices. The price reported represents the weighted average price. The Reporting Person undertakes to provide to the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares sold by the Reporting Person at each separate price within the range. F5 · price: Sales prices range from $18.47 to $18.53 per share, inclusive. Read SEC document |
| July 01, 2022 Filed Jul 5, 2022 20:30 UTC | RELMADA THERAPEUTICS, INC. RLMD · Entity 5498 | Exercise / conversionCommon Stock | 13,755 | $16.00 | $220,080.00 |
DisclosureSEC source: 0001213900-22-037231 · ownership.xml · nonDerivative · entry 4 TRAVERSA SERGIO · CIK 0001565832 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 102,529 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction reported on this Form 4 reflects the exercise of stock options set to expire on July 10, 2022. Read SEC document |
| June 30, 2022 Filed Jul 5, 2022 20:30 UTC | RELMADA THERAPEUTICS, INC. RLMD · Entity 5498 | Exercise / conversionStock Option (right to buy) · Derivative | 16,012 | $0.00 Strike: $16.00 | $0.00 |
DisclosureSEC source: 0001213900-22-037231 · ownership.xml · derivative · entry 8 TRAVERSA SERGIO · CIK 0001565832 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,755 Underlying: Common Stock · 16,012 shares Expires 2022-07-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction reported on this Form 4 reflects the exercise of stock options set to expire on July 10, 2022. F8 · derivative.exercise_date: The options were granted on July 10, 2012 (the "Grant Date"). 25% of the options vested upon the Grant Date and the remaining 75% of the options vested in equal quarterly increments over the next four (4) years, so that the last set of options vested in July 2016. Read SEC document |
| June 30, 2022 Filed Jul 5, 2022 20:30 UTC | RELMADA THERAPEUTICS, INC. RLMD · Entity 5498 | SaleCommon Stock | 10,698 | $19.01 | $203,368.98 |
DisclosureSEC source: 0001213900-22-037231 · ownership.xml · nonDerivative · entry 3 TRAVERSA SERGIO · CIK 0001565832 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 88,774 F2 · shares: The number of securities reported represents an aggregate number of shares sold in multiple open market transactions over a range of sales prices. The price reported represents the weighted average price. The Reporting Person undertakes to provide to the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares sold by the Reporting Person at each separate price within the range. F4 · price: Sales prices range from $19.00 to $19.15 per share, inclusive. Read SEC document |
| June 30, 2022 Filed Jul 5, 2022 20:30 UTC | RELMADA THERAPEUTICS, INC. RLMD · Entity 5498 | SaleCommon Stock | 5,314 | $19.37 | $102,932.18 |
DisclosureSEC source: 0001213900-22-037231 · ownership.xml · nonDerivative · entry 2 TRAVERSA SERGIO · CIK 0001565832 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 99,472 F2 · shares: The number of securities reported represents an aggregate number of shares sold in multiple open market transactions over a range of sales prices. The price reported represents the weighted average price. The Reporting Person undertakes to provide to the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares sold by the Reporting Person at each separate price within the range. F3 · price: Sales prices range from $19.20 to $19.51 per share, inclusive. Read SEC document |
| June 30, 2022 Filed Jul 5, 2022 20:30 UTC | RELMADA THERAPEUTICS, INC. RLMD · Entity 5498 | Exercise / conversionCommon Stock | 16,012 | $16.00 | $256,192.00 |
DisclosureSEC source: 0001213900-22-037231 · ownership.xml · nonDerivative · entry 1 TRAVERSA SERGIO · CIK 0001565832 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 104,786 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction reported on this Form 4 reflects the exercise of stock options set to expire on July 10, 2022. Read SEC document |
| May 25, 2022 Filed May 26, 2022 22:45 UTC | RELMADA THERAPEUTICS, INC. RLMD · Entity 5498 | GrantStock Option (right to buy) · Derivative | 300,000 | $0.00 Strike: $19.03 | $0.00 |
DisclosureSEC source: 0001213900-22-029839 · ownership.xml · derivative · entry 2 TRAVERSA SERGIO · CIK 0001565832 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 300,000 Underlying: Common Stock · 300,000 shares Expires 2031-12-17 F1 · date: The option grant was approved by the Board of Directors of the Company on December 17, 2021, subject to shareholder approval of an amendment to the Company's 2021 Equity Incentive Plan (the "Plan") increasing the number of shares of Common Stock available for the grant of awards under the Plan in an amount sufficient to cover this option grant. Shareholder approval was received for such amendment on May 25, 2022, at the 2022 Annual Meeting of the Company's shareholders. F3 · derivative.exercise_date: 50% of the option shall vest when the Board of Directors or Compensation Committee has determined that 301, 302 and 303 Trials of dextromethadone (REL-1017) in major depressive disorder ("MDD") complete enrollment, as defined in the respective Trial's protocol, with 364 patients per Trial with the last patient in for each trial to be enrolled by December 31, 2022. The remaining 50% of the option shall vest when the Board of Directors or Compensation Committee has determined that 301, 302 and 303 Trials of REL-1017 in MDD report top-line data by December 31, 2023, and meet or exceed their primary and key secondary endpoints as defined in in the respective Trial's protocol. Read SEC document |
| May 25, 2022 Filed May 26, 2022 22:45 UTC | RELMADA THERAPEUTICS, INC. RLMD · Entity 5498 | GrantStock Option (right to buy) · Derivative | 651,821 | $0.00 Strike: $19.03 | $0.00 |
DisclosureSEC source: 0001213900-22-029839 · ownership.xml · derivative · entry 1 TRAVERSA SERGIO · CIK 0001565832 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,143,994 Underlying: Common Stock · 651,821 shares Expires 2031-12-17 F1 · date: The option grant was approved by the Board of Directors of the Company on December 17, 2021, subject to shareholder approval of an amendment to the Company's 2021 Equity Incentive Plan (the "Plan") increasing the number of shares of Common Stock available for the grant of awards under the Plan in an amount sufficient to cover this option grant. Shareholder approval was received for such amendment on May 25, 2022, at the 2022 Annual Meeting of the Company's shareholders. F2 · derivative.exercise_date: The option vests in 16 equal quarterly installments, at 6.25% per quarter, commencing on March 17, 2022. Read SEC document |
| December 17, 2021 Filed Dec 22, 2021 02:31 UTC | RELMADA THERAPEUTICS, INC. RLMD · Entity 5498 | GrantStock Option (right to buy) · Derivative | 492,173 | $0.00 Strike: $19.03 | $0.00 |
DisclosureSEC source: 0001213900-21-066825 · ownership.xml · derivative · entry 1 TRAVERSA SERGIO · CIK 0001565832 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 492,173 Underlying: Common Stock · 492,173 shares Expires 2031-12-17 F1 · derivative.exercise_date: The option vests in 16 equal quarterly installments commencing on March 17, 2022. Read SEC document |
| July 08, 2021 Filed Feb 2, 2023 22:01 UTC | RELMADA THERAPEUTICS, INC. RLMD · Entity 5498 | GiftStock Option (right to buy) · Derivative | 87,500 | $0.00 Strike: $33.43 | $0.00 |
DisclosureSEC source: 0001213900-23-007440 · ownership.xml · derivative · entry 6 TRAVERSA SERGIO · CIK 0001565832 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 162,500 Underlying: Common Stock · 87,500 shares Expires 2031-01-07 F1 · kind: Represents a bona fide gift of stock options to a family trust. An independent trustee is trustee of the trust. F7 · derivative.exercise_date: The options were granted on January 7, 2021. 25% of the options vested one year from the grant date, and thereafter in equal quarterly increments of 6.25% over the following three years. Read SEC document |
| July 08, 2021 Filed Feb 2, 2023 22:01 UTC | RELMADA THERAPEUTICS, INC. RLMD · Entity 5498 | GiftStock Option (right to buy) · Derivative | 93,750 | $0.00 Strike: $33.43 | $0.00 |
DisclosureSEC source: 0001213900-23-007440 · ownership.xml · derivative · entry 5 TRAVERSA SERGIO · CIK 0001565832 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 162,500 Underlying: Common Stock · 93,750 shares Expires 2031-01-07 F1 · kind: Represents a bona fide gift of stock options to a family trust. An independent trustee is trustee of the trust. F6 · derivative.exercise_date: The options were granted on January 7, 2021. 6.25% of the options vest each quarter from the date of grant. Read SEC document |
| July 08, 2021 Filed Feb 2, 2023 22:01 UTC | RELMADA THERAPEUTICS, INC. RLMD · Entity 5498 | GiftStock Option (right to buy) · Derivative | 131,250 | $0.00 Strike: $43.47 | $0.00 |
DisclosureSEC source: 0001213900-23-007440 · ownership.xml · derivative · entry 4 TRAVERSA SERGIO · CIK 0001565832 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 218,750 Underlying: Common Stock · 131,250 shares Expires 2029-12-19 F1 · kind: Represents a bona fide gift of stock options to a family trust. An independent trustee is trustee of the trust. F5 · derivative.exercise_date: The options were granted on December 19, 2019. 6.25% of the options vest each quarter from the date of grant. Read SEC document |
| July 08, 2021 Filed Feb 2, 2023 22:01 UTC | RELMADA THERAPEUTICS, INC. RLMD · Entity 5498 | GiftStock Option (right to buy) · Derivative | 8,231 | $0.00 Strike: $54.00 | $0.00 |
DisclosureSEC source: 0001213900-23-007440 · ownership.xml · derivative · entry 3 TRAVERSA SERGIO · CIK 0001565832 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,019 Underlying: Common Stock · 8,231 shares Expires 2025-02-23 F1 · kind: Represents a bona fide gift of stock options to a family trust. An independent trustee is trustee of the trust. F4 · derivative.exercise_date: The options were granted on February 15, 2015. 6.25% of the options vested each quarter from the date of grant. Read SEC document |
| July 08, 2021 Filed Feb 2, 2023 22:01 UTC | RELMADA THERAPEUTICS, INC. RLMD · Entity 5498 | GiftStock Option (right to buy) · Derivative | 27,123 | $0.00 Strike: $16.00 | $0.00 |
DisclosureSEC source: 0001213900-23-007440 · ownership.xml · derivative · entry 2 TRAVERSA SERGIO · CIK 0001565832 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,165 Underlying: Common Stock · 27,123 shares Expires 2023-09-30 F1 · kind: Represents a bona fide gift of stock options to a family trust. An independent trustee is trustee of the trust. F3 · derivative.exercise_date: The options were granted on September 30, 2013. 25% of the options vested upon the date of grant and the remaining 75% of the options vested in equal quarterly increments over the next four (4) years, so that the last set of options vested in September 2017. Read SEC document |
| July 08, 2021 Filed Feb 2, 2023 22:01 UTC | RELMADA THERAPEUTICS, INC. RLMD · Entity 5498 | GiftStock Option (right to buy) · Derivative | 4,131 | $0.00 Strike: $16.00 | $0.00 |
DisclosureSEC source: 0001213900-23-007440 · ownership.xml · derivative · entry 1 TRAVERSA SERGIO · CIK 0001565832 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,131 shares Expires 2022-07-10 F1 · kind: Represents a bona fide gift of stock options to a family trust. An independent trustee is trustee of the trust. F2 · derivative.exercise_date: The options were granted on July 10, 2012. 25% of the options vested upon the grant date and the remaining 75% of the options vested in equal quarterly increments over the next four (4) years, so that the last set of options vested in July 2016. Read SEC document |
| July 08, 2021 Filed Feb 6, 2023 22:39 UTC Amendment | RELMADA THERAPEUTICS, INC. RLMD · Entity 5498 | GiftStock Option (right to buy) · Derivative | 31,250 | $0.00 Strike: $33.43 | $0.00 |
DisclosureSEC source: 0001213900-23-008514 · ownership.xml · derivative · entry 5 TRAVERSA SERGIO · CIK 0001565832 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 225,000 Underlying: Common Stock · 31,250 shares Expires 2031-01-07 F1 · kind: Represents a bona fide gift of stock options to a family trust. An independent trustee is trustee of the trust. F6 · derivative.exercise_date: The options were granted on January 7, 2021. 6.25% of the options vest each quarter from the date of grant. Read SEC document |
| July 08, 2021 Filed Feb 6, 2023 22:39 UTC Amendment | RELMADA THERAPEUTICS, INC. RLMD · Entity 5498 | GiftStock Option (right to buy) · Derivative | 131,250 | $0.00 Strike: $43.47 | $0.00 |
DisclosureSEC source: 0001213900-23-008514 · ownership.xml · derivative · entry 4 TRAVERSA SERGIO · CIK 0001565832 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 218,750 Underlying: Common Stock · 131,250 shares Expires 2029-12-19 F1 · kind: Represents a bona fide gift of stock options to a family trust. An independent trustee is trustee of the trust. F5 · derivative.exercise_date: The options were granted on December 19, 2019. 6.25% of the options vest each quarter from the date of grant. Read SEC document |
| July 08, 2021 Filed Feb 6, 2023 22:39 UTC Amendment | RELMADA THERAPEUTICS, INC. RLMD · Entity 5498 | GiftStock Option (right to buy) · Derivative | 8,231 | $0.00 Strike: $54.00 | $0.00 |
DisclosureSEC source: 0001213900-23-008514 · ownership.xml · derivative · entry 3 TRAVERSA SERGIO · CIK 0001565832 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,019 Underlying: Common Stock · 8,231 shares Expires 2025-02-23 F1 · kind: Represents a bona fide gift of stock options to a family trust. An independent trustee is trustee of the trust. F4 · derivative.exercise_date: The options were granted on February 15, 2015. 6.25% of the options vested each quarter from the date of grant. Read SEC document |
| July 08, 2021 Filed Feb 6, 2023 22:39 UTC Amendment | RELMADA THERAPEUTICS, INC. RLMD · Entity 5498 | GiftStock Option (right to buy) · Derivative | 27,123 | $0.00 Strike: $16.00 | $0.00 |
DisclosureSEC source: 0001213900-23-008514 · ownership.xml · derivative · entry 2 TRAVERSA SERGIO · CIK 0001565832 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,165 Underlying: Common Stock · 27,123 shares Expires 2023-09-30 F1 · kind: Represents a bona fide gift of stock options to a family trust. An independent trustee is trustee of the trust. F3 · derivative.exercise_date: The options were granted on September 30, 2013. 25% of the options vested upon the date of grant and the remaining 75% of the options vested in equal quarterly increments over the next four (4) years, so that the last set of options vested in September 2017. Read SEC document |
| July 08, 2021 Filed Feb 6, 2023 22:39 UTC Amendment | RELMADA THERAPEUTICS, INC. RLMD · Entity 5498 | GiftStock Option (right to buy) · Derivative | 4,131 | $0.00 Strike: $16.00 | $0.00 |
DisclosureSEC source: 0001213900-23-008514 · ownership.xml · derivative · entry 1 TRAVERSA SERGIO · CIK 0001565832 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,131 shares Expires 2022-07-10 F1 · kind: Represents a bona fide gift of stock options to a family trust. An independent trustee is trustee of the trust. F2 · derivative.exercise_date: The options were granted on July 10, 2012. 25% of the options vested upon the grant date and the remaining 75% of the options vested in equal quarterly increments over the next four (4) years, so that the last set of options vested in July 2016. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.